Melanotan II

Melanotan 2 (MT-2) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH) with the molecular formula C50H69N15O9 and CAS number 121062-08-6. It functions as a non-selective agonist of melanocortin receptors MC1, MC3, MC4, and MC5, demonstrating up to 1000 times greater potency than endogenous α-MSH. Originally developed for photoprotection through melanogenesis, clinical research has primarily focused on its effects on sexual function, with multiple double-blind placebo-controlled trials demonstrating significant erectogenic properties in men with both psychogenic and organic erectile dysfunction. Additional research areas include metabolic effects, neuroprotection, and appetite suppression. Despite showing clinical efficacy in phase I trials, Melanotan 2 has never received regulatory approval from the FDA, EMA, TGA, or other major health authorities. It remains widely available through unregulated online markets as an unapproved cosmetic tanning agent and sexual enhancement compound, with significant safety concerns including associations with melanoma development, dysplastic nevi, nausea, cardiovascular effects, and unknown long-term risks due to lack of comprehensive safety studies.

Skin Pigmentation and Tanning

• Melanogenesis Induction: Activates MC1 receptors to stimulate melanin production, producing measurable skin darkening in human subjects after only 5 low doses (0.01-0.03 mg/kg) without UV exposure ^[1]
• Superpotent α-MSH Activity: Demonstrates up to 1000-fold greater potency than endogenous alpha-melanocyte stimulating hormone in vitro, with high-affinity binding (Ki values: MC1 0.67 nM, MC4 6.6 nM, MC3 34 nM, MC5 46 nM)
• Photoprotection Potential: Originally developed to provide UV-protective skin pigmentation, though clinical efficacy for melanoma prevention remains unproven

Sexual Function and Libido

• Erectile Function Enhancement: In double-blind placebo-controlled trials, induced spontaneous erections in 85% (17/20) of men with erectile dysfunction, achieving mean tip rigidity >80% for 38-45 minutes versus 2-3 minutes with placebo (p<0.005) ^[2][3][4]
• Sexual Desire Augmentation: Increased sexual desire reported in 68% of doses versus 19% with placebo (p<0.01) in men with ED; works through MC4 receptor activation in the central nervous system ^[2][4]
• Efficacy Across ED Types: Demonstrates erectogenic properties in both psychogenic and organic erectile dysfunction, including patients with diabetes, vascular disease, and other organic risk factors ^[3][4]
• Female Sexual Response: Enhanced proceptive sexual behaviors (solicitation, hops/darts, ear wiggling) in female rat models, suggesting potential applications for hypoactive sexual desire disorder ^[10]

Metabolic and Body Composition Effects

• Persistent Weight Reduction: Chronic activation of melanocortin system produces sustained body mass reduction without long-term caloric restriction; body weight remained reduced even after food intake returned to baseline in 40-day rat studies ^[6]
• Adipose Tissue Reduction: Peripheral administration led to weight loss affecting both visceral and subcutaneous fat compartments, with greater fat loss than pair-fed controls, indicating mechanisms beyond appetite suppression alone ^[7]
• Insulin Sensitivity Enhancement: Central administration acutely increased insulin-mediated glucose disposal (151 vs 108 μmol·min⁻¹·kg⁻¹) and skeletal muscle Glut4 mRNA expression in a tissue-specific manner ^[8]
• Appetite Suppression: Dose-dependent reduction in food intake through MC3/MC4 receptor activation, though effects are transient while body composition changes persist ^[6]

Neuroprotection

• Peripheral Nerve Regeneration: Significantly enhanced recovery of sensory function following sciatic nerve crush lesions in rats at doses of 20 μg/kg per 48 hours ^[5]
• Neuroprotective Properties: Partially protected peripheral nerves from cisplatin-induced toxic neuropathy, representing the first evidence of dual regenerative and protective effects for this compound ^[5]

Clinical Safety Profile

• Common Side Effects: Nausea (most frequent, sometimes severe in ~13% at 0.025 mg/kg), yawning, stretching responses, facial flushing, somnolence, fatigue, decreased appetite, and spontaneous erections in males ^[1][2][3]
• Severe Adverse Events: Case reports document rhabdomyolysis, renal dysfunction, sympathomimetic overdrive, elevated blood pressure, and systemic toxicity requiring medical intervention
• Dermatological Risks: Multiple documented cases of eruptive dysplastic nevi, rapid transformation and darkening of existing moles, and development of new atypical nevi within weeks of use ^[12][13]
• Melanoma Association: At least five case reports of melanoma diagnosed during or after Melanotan II use, including melanoma in situ and invasive melanomas (Breslow depths 0.3-1mm) in young users (ages 20-42) ^[9][12][13]
• Diagnostic Masking: Darkening of existing pigmented lesions can mask early melanoma signs and delay cancer diagnosis, a critical safety concern

Regulatory Status

• No Regulatory Approval: Not approved by FDA (US), EMA (Europe), TGA (Australia), MHRA (UK), or any major health authority for any indication
• FDA Warning (2007): Issued public notice advising consumers to stop using Melanotan II as an unapproved drug with no established safety or efficacy data
• International Warnings: Danish, Norwegian, Swedish, and UK medicines agencies have issued warnings; deemed illegal to sell in UK, Australia, and New Zealand
• Australian Scheduling: TGA classified as Schedule 4 (prescription-only) in 2017, with import restrictions; unlawful to import without prescription from registered Australian practitioner
• Unregulated Market: Widely available through illegal online channels, tanning salons, and beauty parlors with no quality control, purity standards, or safety oversight

Research Gaps and Concerns

• No Long-Term Safety Data: Absence of comprehensive Phase II/III trials or long-term safety studies; unknown effects of chronic use over months to years
• Lack of Standardization: Unregulated products may contain contaminants, incorrect dosages, or degraded compounds with unknown toxicity profiles
• Cancer Risk Uncertainty: Theoretical concern that chronic MC1 receptor stimulation combined with UV exposure could promote melanoma development, though causation not definitively established
• Cardiovascular Effects: Limited data on long-term cardiovascular impacts; sympathomimetic effects raise concerns for hypertensive patients
• Drug Interactions: Insufficient research on interactions with other medications or compounds
• Dose-Response Safety: No established safe dosing range; clinical trials used 0.025 mg/kg, but unregulated use involves highly variable and often excessive doses